nolasiban
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02310802)
Timeline
Indications
Mechanism of action
- Oxytocin receptorANTAGONIST
OXTR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CO/N=C1/C[C@@H](CO)N(C(=O)c2ccc(-c3ccccc3C)cc2)C1- Mol. weight
- 338.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1254025 ↗
Also known as
- nolasiban
- nolasiban
- obe001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03758885 | Phase 3 | Jan 10, 2019 | ObsEva SA |
| NCT03081208 | Phase 3 | Mar 6, 2017 | ObsEva SA |
| NCT02326142 | Phase 2 | Mar 1, 2015 | ObsEva SA |
| NCT02310802 | Phase 2 | Nov 1, 2014 | ObsEva SA |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ObsEva SA | For profit | 4 | 4 | 2 | 2014 |
1 organizations
Page 1 / 1